mRNA Tuberculosis Vaccine Moves Toward First-in-Human
Quick Facts
Why is a new tuberculosis vaccine needed?
The World Health Organization's Global Tuberculosis Report estimated that roughly 10.8 million people fell ill with TB in 2023 and about 1.25 million died, making it one of the world's deadliest infectious diseases. The BCG vaccine, first used in humans in 1921, remains the only licensed vaccine. It is effective at reducing severe forms of TB in young children, such as meningitis, but its protection against lung disease in adults, who drive transmission, is variable and often wanes.
Rising drug-resistant TB adds urgency. Treatment regimens can last months and cause significant side effects, and multidrug-resistant forms are harder to treat. A vaccine that prevents disease in adolescents and adults could reduce transmission and the need for prolonged therapy, which is why TB vaccine development is a global research priority.
How would a dendritic cell-targeted mRNA vaccine work?
According to the PR Newswire announcement, Akagera Medicines received a $7.8 million grant expansion to advance a dendritic cell-targeted mRNA vaccine candidate toward a first-in-human trial. Dendritic cells capture antigens and present them to T cells, orchestrating the adaptive immune response. Because protection against TB is thought to depend heavily on cell-mediated immunity, particularly T cells that activate macrophages, delivering antigen instructions specifically to dendritic cells is intended to sharpen and strengthen that response.
mRNA technology gained wide visibility during the COVID-19 pandemic and allows rapid design and manufacture of vaccines encoding selected antigens. Applying it to TB poses distinct challenges, because the bacterium causes a chronic infection and there is no fully validated correlate of protection to guide development. Targeted delivery may help, but it will need to be proven in carefully designed human studies.
What happens before this vaccine could reach patients?
A first-in-human trial usually enrolls a small number of healthy volunteers to assess safety, tolerability and immune responses at different doses. If results are encouraging, later phases test whether the vaccine actually prevents TB, which requires large populations and long follow-up in high-burden settings. Other TB vaccine candidates, such as M72/AS01E, are already in late-stage efficacy testing, setting a benchmark for what the field hopes to achieve.
Grant funding of this kind helps bridge the preclinical-to-clinical gap, which is often a bottleneck in vaccine development for diseases that primarily affect lower-income regions and have limited commercial incentives. Even so, patients and health systems should view this as an early step, with no guarantee that the candidate will ultimately succeed.
Frequently Asked Questions
Yes. BCG is still given in many countries, mainly to infants, because it helps prevent severe childhood TB. Its protection against adult pulmonary TB is limited and variable.
No. The candidate described in the announcement is moving toward its first human trial, so it is not available outside of research settings.
Yes, most TB is curable with a course of antibiotics taken as prescribed, though treatment lasts months and drug-resistant forms are more difficult to treat.
References
- PR Newswire. Akagera Medicines Receives $7.8 Million Grant Expansion to Advance Dendritic Cell-Targeted mRNA Tuberculosis Vaccine Toward First-in-Human Trial. November 2026.
- World Health Organization. Global Tuberculosis Report 2024.
- World Health Organization. Tuberculosis fact sheet.